The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma
Nishikawa H, Osaki Y, Arimoto A, Kita R, Kimura T. Anticancer Res. 2013 May;33(5):2211-9.
Source
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan. h-nishikawa@osaka-med.jrc.or.jp.
Abstract
Background/Aim: We aimed to examine the relationship between antibodies to hepatitis B core antigen (anti-HBc) positivity and survival in patients with non-B non-C hepatocellular carcinoma (NBNC-HCC) who underwent curative treatment.
PATIENTS AND METHODS:
A total of 260 patients with NBNC-HCC who underwent curative therapy were analyzed. They included 124 anti-HBc-positive patients (47.7%) and 136 anti-HBc-negative patients (52.3%). Overall survival (OS) and recurrence-free survival (RFS) rates were compared.
RESULTS:
The 3-year cumulative OS rates were 75.9% in the anti-HBc-positive group and 82.3% in the anti-HBc-negative group (p=0.069). The corresponding RFS rates were 29.8% in the anti-HBc-positive group and 43.0% in the anti-HBc-negative group (p=0.001). Multivariate analyses identified anti-HBc positivity (p=0.006), aspartate aminotransferase ≥40 IU/l (p=0.037) and des-γ-carboxy prothrombin ≥100 mAU/ml (p=0.046) as significant adverse predictors were linked to RFS.
CONCLUSION:
Anti-HBc positivity can be a useful predictor for recurrence in patients with NBNC-HCC after curative therapy.